Journal of Ophthalmology / 2019 / Article / Tab 1

Clinical Study

Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis

Table 1

Comparison of primary outcome measures.

ItemsGroupsV0V1V2V3V4

Quality of meibum (upper eyelid)Treatment group15.83 ± 4.4312.17 ± 4.597.69 ± 3.353.79 ± 2.232.86 ± 1.44<0.001
Control group15.05 ± 3.2411.50 ± 2.999.82 ± 2.847.09 ± 2.715.77 ± 1.74<0.001
0.4650.5410.014<0.001<0.001

Quality of meibum (lower eyelid)Treatment group13.07 ± 4.929.00 ± 5.086.17 ± 3.893.43 ± 2.962.55 ± 1.61<0.001
Control group13.14 ± 4.9710.14 ± 4.008.82 ± 3.296.77 ± 2.784.59 ± 1.87<0.001
0.9600.3660.008<0.001<0.001

Expressibility of the Meibomian glands (upper eyelid)Treatment group1.62 ± 0.761.14 ± 0.650.60 ± 0.500.05 ± 0.220.10 ± 0.30<0.001
Control group1.73 ± 0.531.68 ± 0.571.27 ± 0.451.18 ± 0.591.18 ± 0.50<0.001
0.0520.002<0.001<0.001<0.001

Expressibility of the Meibomian glands (lower eyelid)Treatment group1.67 ± 0.570.95 ± 0.620.55 ± 0.500.05 ± 0.220.00 ± 0.00<0.001
Control group1.91 ± 0.531.55 ± 0.511.14 ± 0.561.00 ± 0.620.73 ± 0.70<0.001
0.102<0.001<0.001<0.001<0.001

Changes of eyelid margin (upper eyelid)Treatment group2.67 ± 0.722.31 ± 0.711.69 ± 0.711.21 ± 0.810.71 ± 0.71<0.001
Control group2.68 ± 0.652.36 ± 0.492.05 ± 0.491.45 ± 0.510.91 ± 0.43<0.001
0.9340.7520.0410.2120.242

Changes of eyelid margin (lower eyelid)Treatment group2.31 ± 0.601.90 ± 0.661.10 ± 0.760.60 ± 0.660.31 ± 0.47<0.001
Control group2.50 ± 0.672.18 ± 0.501.55 ± 0.671.18 ± 0.590.68 ± 0.57<0.001
0.2540.0880.0220.0010.007

value of one-way repeated measure analysis of variance to compare data for each group at different time points; value of multivariate analysis to compare the treatment and control groups at a specific time point.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.